Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection.

Treatment with pegylated interferon alpha-2b (PEGIFN) plus ribavirin (RBV) is standard therapy for patients with chronic hepatitis C. Although the effectiveness, patients with high titres of group Ib hepatitis C virus (HCV) respond poorly compared to other genotypes. At present, we cannot predict th...

Full description

Bibliographic Details
Main Authors: Tetsuro Takayama, Hirotoshi Ebinuma, Shinichiro Tada, Yoshiyuki Yamagishi, Kanji Wakabayashi, Keisuke Ojiro, Takanori Kanai, Hidetsugu Saito, Toshifumi Hibi, Keio Association for the Study of Liver Diseases
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3229481?pdf=render